Replies to post #83493 on Biotech Values

[DewDiligence]

One of my co-workers had an emergency heart-cath this past week & ended up in the ICU after developing an adverse reaction to the anticoagulant. I haven't gotten all the details but I'm assuming they received Angiomax.

If it was indeed an anticoagulant (rather than an antiplatelet drug) that caused the problem, the drug was likely Angiomax or unfractionated heparin.

MNTA is a pretty exciting company, but the regulatory & legal hurdles are frustrating.

If not for these frustrations, the current valuation would be much higher and your potential upside would be smaller :- )

Looks like there is plenty of room for M118 in the cath lab.

MNTA’s intention is to show that M118 is uniquely suited for use across all segments of the ACS indication: in the ER, in the OR, and in the cath lab. Regards, Dew